Close menu




January 18th, 2022 | 13:07 CET

Ayurcann, Novavax, Covestro - The stragglers are coming!

  • Cannabis
Photo credits: pixabay.com

Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: AYURCANN HOLDINGS CORP | CA05476A1012 , NOVAVAX INC. DL-_01 | US6700024010 , COVESTRO AG O.N. | DE0006062144

Table of contents:


    Ayurcann - Fast growing service provider

    During the first cannabis boom, the industry stars were Tilray, Canopy Growth and Aurora Cannabis, some of whose stock market values exceeded USD 1 billion in 2018. Yet all of these companies have one thing in common: none are making a profit yet. In contrast, Ayurcann Holdings, founded in 2018, is in a steep and, in comparison to the peer group, profitable growth phase.

    Ayurcann's fiscal year ended June 30. The Canadians reported an increase in revenue to more than CAD 7 million. That is up 1,149% from fiscal 2020, and operating income also grew 440% to about CAD 2 million. The latest quarterly figures for the period ending September 30 confirmed the positive trend, with revenues of CAD 1.9 million, up from CAD 0.8 million for the same period last year.

    "We are excited that our revenues are growing consistently. Our margins are robust and we are increasingly profitable. We are proud to be one of the few companies in our peer group to show increasing revenues and positive operating income while maintaining profitability," said Igal Sudman, CEO of Ayurcann.

    The Toronto-based company is a leading post-harvest solutions provider focused on providing and developing custom pharmaceutical-grade processes and products for the edible and medical cannabis industries in Canada. In doing so, Ayurcann continues to focus on growth with the expansion of the Pickering facility up to 300,000kg of input biomass to accommodate the growing customer base of over 40 international brands licensed in Canada, including XPlor from the UK as well as Green Bee, Her Highness from the US and Innocan Pharma from Israel.

    Marketplace was also launched as another direct sales channel, allowing qualified patients to access various products in the portfolio. With a market capitalization of only CAD 22 million, a significant increase in sales while maintaining profitability is not unlikely as the overall market continues to explode. The Canadian cannabis market is expected to grow to around CAD 10 billion by 2025.

    Novavax - Starting signal for the share?

    The share price performance of the vaccine producer Novavax resembles a rollercoaster ride. After jumping from USD 3.86 at the beginning of 2020 to USD 331.68 within 12 months, the protein vaccine manufacturer has corrected to currently USD 110.82. In the area around USD 100, the share may have found a bottom to start a renewed run to the upside.

    Fundamentally, the course has been set. The drug became the fifth vaccine to be approved by the European Medicines Agency (EMA) at the end of last year. Novavax CEO Stanley Erck announced at the JP Morgan Healthcare Conference that the first doses of the vaccine would be delivered soon.

    So far, the Company has signed supply contracts for two billion vaccine doses, some of which still have to be produced and delivered. The EU had already signed contracts with Novavax last August and expect to receive around 69 million doses in the first two quarters. The German health minister expects the first delivery of 1.75 million doses to be available from February 21. Much of the supply is likely to go to poorer nations secured by the Gavi and COVAX vaccine initiatives.

    Covestro - Green hydrogen from Down Under

    Hydrogen is seen as the missing piece of the puzzle in the climate turnaround. Especially when used in the transportation sector, green hydrogen is considered the fuel of the future. However, prices are still too high for the gas to be used as the future energy source and as a substitute for fossil fuels. However, experts believe that the price could fall by around 80%, making green hydrogen as affordable as diesel.

    The chemical group is already making provisions for the future. In its plants in Asia, North America and Europe, Covestro plans to use environmentally friendly hydrogen produced in Australia in the future. A long-term supply agreement is planned with the Australian manufacturer Fortescue Future Industries. Covestro CEO Markus Steilemann described the transition to using green hydrogen and its derivatives as a "significant step" in the effort to offer more sustainable products.


    Despite a cannabis market that continues to grow strongly, shares in the sector are in a three-year correction phase. Ayurcann, founded in 2018 with a current market capitalization of CAD 22 million, is profitable in contrast to its peer group and continues to grow dynamically. At Novavax, the delivery of the first vaccine doses could give the share price a renewed boost. Covestro's prospects remain good with the course set for future growth.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST

    BioNTech, XPhyto, Valneva - It is over!

    • Biotechnology
    • Covid19
    • Cannabis

    In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.

    Read

    Commented by Nico Popp on September 1st, 2022 | 14:05 CEST

    New trending stock in the wings? Plug Power, Cardiol Therapeutics, BioNTech

    • Biotechnology
    • Cannabis
    • Hydrogen

    The markets want to go up! Last Friday, the Fed shock worried the markets, but today, even speculative stocks are picking up again. Especially stocks that were long considered deregistered can quickly develop potential. One example is Plug Power. Here, new demand in the wake of high energy prices meets good products. We explain the secret to the success of comeback stocks, using Plug Power as an example, and highlight new opportunities.

    Read

    Commented by Carsten Mainitz on February 4th, 2022 | 12:22 CET

    Novavax, Cardiol, MorphoSys - Here's the second wave of Corona vaccine plays!

    • Cannabis

    The number of new Corona infections reported to the Robert Koch Institute (RKI) within one day has reached an all-time high. 236,120 additional cases were recorded, bringing the number of people in Germany who were confirmed to be infected with Sars-CoV-2 to 10.4 million. However, the number of unreported cases is significantly higher. Vaccine manufacturers from the early days have been able to clear the table in recent months, and now new companies such as Novavax and Valneva are entering the scene. But not all innovative approaches to fighting Corona are on the radar of investors. These are perfect conditions for a second share price wave.

    Read